Biotech and Pharmaceutical IPOs in 2016

AC Immune SA (ACIU) (IPO September 23: biopharmaceutical company focused on diseases that are associated with protein misfolding)

Aeglea BioTherapeutics, Inc. (AGLE) (IPO April 7, 2016: biotech company focused on therapeutics for the treatment of inborn errors of metabolism (IEM) and cancer)

Audentes Therapeutics, Inc. (BOLD) (IPO July 20, 2016: biotech company focused on therapy treatments for rare diseases)

Avexis Inc. (AVXS) (IPO February 11, 2016: gene therapy company with a focus on rare neurological genetic diseases)

AzurRx BioPharma, Inc. (AZRX) (IPO October 11, 2016: development stage biopharmaceutical company focused on gastrointestinal disorders)

Beigene, Ltd. (BGNE) (IPO February 3, 2016: biopharmaceutical company with therapeutics designed to treat cancer)

Cellect Biotechnology Ltd. (APOP) (IPO July 29, 2016: biotech company with functional stem cells selection platform)

Clearside Biomedical, Inc. (CLSD) (IPO June 2, 2016: biopharmaceutical company focused on therapies for blinding eye diseases)

Corvus Pharmaceuticals, Inc. (CRVS) (IPO March 23, 2016: biopharmaceutical company focused on immuno-oncology therapies for cancer)

CRISPR Therapeutics (CRSP) (IPO October 19, 2016: Switzerland, gene editing)

Editas Medicine, Inc. (EDIT) (IPO February 3, 2016: Genome editing company)

Gemphire Therapeutics Inc. (GEMP) (IPO August 5, 2016: biopharmaceutical company focused on therapies to treat dyslipidemia)

Hutchison China MediTech Limited (HCM) (IPO March 17, 2016: biopharmaceutical company focused on immunological diseases and oncology in addition to consumer health products)

Intellia Therapeutics, Inc. (NTLA) (IPO May 6, 2016: gene editing company)

Kadmon Holdings, Inc. (KDMN) (IPO July 27, 2016: biopharmaceutical company developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases)

Merus N.V. (MRUS) (IPO May 19, 2016, Netherlands: immuno-oncology company)

Motif Bio plc (MTFB) (IPO November 18, 2016: biopharmaceutical company, development of antibiotics for infections)

Myovant Sciences Ltd. (MYOV) (IPO October 27, 2016: biopharmaceutical company, women’s health and other endocrine-related disorders)

Oncobiologics, Inc. (ONS) (IPO May 13, 2016: biopharmaceutical company focused on biosimilar therapeutics)

Phaserx, Inc. (PZRX) (IPO May, 18 2016: biopharmaceutical company focused on treatments for enzyme deficiencies in the liver)

Proteostasis Therapeutics, Inc. (PTI) (IPO February 11, 2016: Biopharmaceutical company with an initial focus on cystic fibrosis)

Protagonist Therapeutics, Inc. (PTGX) (IPO August 11, 2016: biopharmaceutical company with a platform focused on discovering and developing peptide-based new chemical entities)

Ra Pharmaceuticals, Inc. (RARX) (IPO October 26, 2016: biopharmaceutical company, therapeutics for complement-mediated diseases)

Reata Pharmaceuticals, Inc. (RETA) (IPO May 26, 2016: biopharmaceutical company focused on developing drugs that modulate the activity of important regulatory proteins)

Selecta Biosciences, Inc. (SELB) (IPO June 22, 2016: clinical-stage biopharmaceutical company focused on products designed to modulate the immune system)

Spring Bank Pharmaceuticals, Inc. (SBPH) (IPO May 6, 2016: biopharmaceutical company focused on viral diseases)

Syndax Pharmaceuticals, Inc. (SNDX) (IPO March 3, 2016: biopharmaceutical company engaged in the development of cancer treatments)

Syros Pharmaceuticals, Inc. (SYRS) (IPO June 30, 2016: biopharmaceutical company, gene control medicines)